Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease is pleased to announce that Dr. Kira Holmström, Head of Biomarker Research at Herantis, has been selected to present at the 19th Annual Biomarkers Congress taking place February 29th to March 1th in London, UK.

The title of Dr. Holmström’s presentation is:

• Biomarker translation from preclinical to clinical in disease modifying therapeutics

Developing biomarkers for clinical use in the CNS space has its challenges, especially as there is a lack of established biomarkers. The tides are however changing and there is light at the end of the tunnel, as we finally see biomarker driven disease modifying therapies being approved by regulatory authorities. New and old challenges about the translational aspects of biomarker development for disease modifying therapies will be discussed in the light of Herantis’ clinical program.

Herantis management will also participate at the Biotechgate Digital Partnering event from February 26th to March 1st. For more information and to schedule a meeting, please contact us at ir@herantis.com.

About 19th Annual Biomarkers Congress:
The aim of this congress is to unveil the forefront of biomarker trends and tools. This event assembles top experts from global pharmaceutical organizations, groundbreaking biotech companies, and esteemed academic institutions, all engaged in diverse therapeutic areas and stages of drug development.

About Biotechgate Digital Partnering:
This event is focusing on companies developing drugs, diagnostics and medical devices. The main objective of the event is to provide a platform for business development in the field of licensing and collaboration.

For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com